Proof That Cannabis Needs to Be Part of Your Treatment Protocol for Breast Cancer - RxLeaf

Proof That Cannabis Needs to Be Part of Your Treatment Protocol for Breast Cancer

Soumya Nalam
Cancer Patient Woman in Bed

These studies tell us that cannabis is effective in reducing tumor growth, size, and metastasis for breast cancer.

Breast cancer is the most common, and is now the second leading cause of cancer death in American women (lung cancer is number one). Metastasis is the big killer, responsible for approximately 90% of breast cancer-related deaths.  This disease requires treatment using additional alternative therapies that have increased efficacy and low toxicity.

Breast Cancer

Image Credit: Guschen Kova

Studies suggest that regulation issues within the endocannabinoid system may trigger cancer by fostering the body conditions that allow mutated cells to proliferate and migrate. Cannabinoid receptors CB1 (central) and CB2 (peripheral) have been shown to be over-expressed in tumor cells (compared with normal cells) for various types of cancers, especially breast and liver cancers.

Black and white image of woman covering breasts with her hands

Image Credit: Sutterstock

Synthetic Cannabinoids and Breast Cancer

Given that breast cancer tumors have more CB2 receptors than healthy tissue does, a team of researchers set out to find out if cannabinioids could be used to stop the tumor growth. The study used a synthetic CB2 agonist (a chemical that binds to the receptor and activates it). THC, found in the cannabis plant, is natural agonist of the CB2 (and CB1) receptors.

Mice treated with the synthetic CB2 agonist saw 40-50% reduction in tumor growth and 65-80% reduction in metastasis. Additionally, when the cancerous mice were also treated with a CB2 antagonist (a chemical that prevents receptor activation), these benefits were reversed. This tells us that endocannabinoid receptors are involved in modulation of tumor growth and metastasis.

Close up woman rolling a joint

Image Credit: CAPJAH

Patients (91%) with the HER-2 mutation (ErbB2-positive tumors) over express CB2 receptor. HER-2 is a very aggressive form of breast cancer, compared to other forms.  Fortunately, both THC (phytocannabinoid) and the synthetic CB2 agonist reduced tumor growth, tumor number, and the amount/severity of metastases in animal models for HER-2.

Cannabinoids also have a modulatory effect on triple negative breast cancer cells (cancer cells that lack HER-2/ErbB2, estrogen and/or progesterone receptors).

Interestingly, COX-2 is an inflammatory enzyme that is expressed in 40% of human cases for invasive breast cancer.  This enzyme promotes metastasis. Studies have shown that a cannabinoid called cannabidiolic acid (CBDa) is a selective COX-2 inhibitor. This means that CBDa is able to inhibit COX-2 by down-regulating and also through the suppression of genes that are positively involved in the metastasis of cancer cells.

THC chemical formula

Image Credit: Shutterstock

Cannabinoids exert their anti-cancer effects by binding to CB1 and CB2 receptors. Since these anti-tumorigenic effects are dependent on the cell line or tumor type, the endocannabinoid system provides a targeted treatment of cancer by demonstrating selective action on tumor cells while not affecting normal cells.

Stathmin and Tau Protein Regulation

Microtubule Associated Proteins (MAPs) stathmin and tau are the key proteins in cancer metastasis. Both interact with microtubules (responsible for forming cytoplasm, the living matter of all cells) to regulate their function.

Cancer Patient Woman in Bed

Image Credit: ESB Professionals

Stathmin, a phosphoprotein, can be used to measure and predict the aggressiveness in many cancers, including endometrial and breast. High stathmin levels in a primary tumor is an identifier of high risk for recurrent disease in patients and also predicts a poor overall survival rate, along with a less robust response to chemotherapy. When stathmin and tau expression levels were measured in breast cancer cells, the analysis showed that the ratio of high tau: stathmin is prognostic for improved survival in breast cancer patients.

cannabis plant

Image Credit: Danaan

A Cannabis sativa extract effectively reduces tau and stathmin gene expression in cancer cells, and it significantly decreases the migration of cancers cell lines. Growing evidence indicates that tau can provide a selective advantage during metastasis in cancer patients. Since this protein contributes to the metastatic efficiency of breast tumor cells, anti-tau drugs may potentially inhibit tumor metastasis.

This indicates that cannabis-based medicines are effective adjunctive treatment in cancer patients.








Soumya Nalam

An expert content strategist with over a decade's experience. A double gold medalist with a Master's in Life Sciences (Biochemistry & Molecular Biology). Editor-in-charge at CureJoy, Senior Publishing Specialist and Reuters and Optimization Specialist at Google AdSense.

No Comments

Post a Comment